What is the purpose of this trial?
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS. Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions. Participants will be randomized to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52.
Ages: 18 - 55 years
Genentech Foundation for Biomedical Sciences
Start Date: 06/29/2016
End Date: 09/30/2018
Last Updated: 02/22/2018
Study HIC#: 1602017292